Anti-infective monoclonal antibodies: Perils and promise of development

Nature Reviews Drug Discovery

Volumn 5, Issue 3, 2006, Pages 191-195

  Reichert, Janice M ^a   Dewitz, Matthew C ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF LAW   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTHRAX VACCINE; ANTIINFECTIVE AGENT; AUROGRAB; BACTERIAL VACCINE; CANDIDA ALBICANS VACCINE; CENTOXIN; CIPROFLOXACIN; CYTOMEGALOVIRUS VACCINE; EDOBACOMAB; ESCHERICHIA COLI VACCINE; FUNGUS VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HEPATITIS C VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MARAVIROC; MONOCLONAL ANTIBODY; NUMAX; PALIVIZUMAB; PSEUDOMONAS VACCINE; RABIES VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RIBAMIDINE; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; SMALLPOX VACCINE; STAPHYLOCOCCUS VACCINE; UNINDEXED DRUG; VIRUS VACCINE; WEST NILE VACCINE;

ANTHRAX; ARTICLE; ASPERGILLOSIS; B LYMPHOCYTE; BACTERIAL INFECTION; BIOLOGICAL WARFARE; BIOTECHNOLOGY; CANDIDIASIS; CLINICAL TRIAL; CORONAVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; DRUG RESEARCH; DRUG TARGETING; ENTEROBACTER INFECTION; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; GRAM NEGATIVE INFECTION; GRAM NEGATIVE SEPSIS; HEMOLYTIC UREMIC SYNDROME; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IMMUNOPATHOLOGY; INFECTION; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; RABIES; SEVERE ACUTE RESPIRATORY SYNDROME; SMALLPOX; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; TREATMENT OUTCOME; UNITED STATES; VIRUS INFECTION; WEST NILE FLAVIVIRUS;

ANTI-INFECTIVE AGENTS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; DRUG APPROVAL; DRUG DESIGN; HUMANS;

EID: 33644782751     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd1987     Document Type: Article

References (15)

1. Reichert, J. M. Monoclonal antibodies in the clinic. Nature Biotechnol. 19, 819-822 (2001).
2. Reichert, J. M. Therapeutic monoclonal antibodies: Trends in development and approval in the US. Curr. Opin. Mol. Ther. 4, 110-118 (2002).
3. Reichert, J. & Pavlou, A. Monoclonal antibodies market. Nature Rev. Drug Discov. 3, 383-384 (2004).
4. Reichert, J. M., Rosensweig, C. J., Faden, L. B. & Dewitz, M. C. Monoclonal antibody successes in the clinic. Nature Biotechnol. 23, 1073-1078 (2005).
5. Hector, R. F., Collins, M. S. & Pennington, J. E. Treatment of experimental Pseudomonas aeruginosa pneumonia with a human IgM monoclonal antibody. J. Infect. Dis. 160, 483-489 (1989).
6. Khazaeli, M. B., Conry, R. M. & LoBuglio, A. F. Human immune response to monoclonal antibodies. J. Immunother. 15, 42-52 (1994).
7. Angus, D. C. et al. E5 murine monoclonal antiendotoxin antibody in Gram-negative sepsis: A randomized controlled trial. JAMA 283, 1723-1730 (2000).
8. Inglis, T. J. J. et al. Monoclonal antiendotoxin agent HA-1A (Centoxin). Lancet 341, 303 (1993).
9. National Institutes of Health web site [online], (2005).
10. Garber, D. A., Silvestri, G. & Feinberg, M. B. Prospects for an AIDS vaccine: Three big questions, no easy answers. Lancet Infect. Dis. 4, 397-413 (2004).
11. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711-715 (2004).
12. Project BioShield Act of 2004. US Public Law 108-276 (2004 July 21); 42 USC 247d-6a; 1 18 Stat. 835.
13. Usdin, S. Bioshield hammered. BioCentury 13(32), A14 (2005).
14. Project BioShield II Act of 2005. S.975 (2005 April 29).
15. Federal Register. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. 67, 37988-37998 (2002).